Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating post-myocardial-infarction ventricular remodeling

A technology for ventricular remodeling and myocardial infarction, applied in the field of medicine, can solve the problem of lack of drugs for ventricular remodeling after myocardial infarction

Active Publication Date: 2018-05-18
岳红
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinically, there is still a lack of therapeutic drugs for ventricular remodeling after myocardial infarction.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating post-myocardial-infarction ventricular remodeling
  • Pharmaceutical composition for treating post-myocardial-infarction ventricular remodeling
  • Pharmaceutical composition for treating post-myocardial-infarction ventricular remodeling

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0032]

[0033]Excipients: hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose and water. The amount of hydroxypropyl-β-cyclodextrin is 1.2 times of the weight of quercetin, the amount of low-substituted hydroxypropyl cellulose is 0.3 times of the weight of quercetin, and the amount of hydroxypropyl methylcellulose is 0.04 times of the weight of quercetin times.

[0034] Preparation:

[0035] Step 1: Take the prescribed amount of quercetin, miltefosine, hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropyl cellulose, and hydroxypropyl methylcellulose and pass through an 80-mesh sieve for later use, and take hydroxypropyl cellulose Base methyl cellulose is added water to make the aqueous solution that mass percent concentration is 2% for subsequent use;

[0036] Step 2: Take the prescribed amount of hydroxypro...

Embodiment 2

[0038] Example 2 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0039]

[0040] Excipients: hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose and water. The amount of hydroxypropyl-β-cyclodextrin is 1.2 times of the weight of quercetin, the amount of low-substituted hydroxypropyl cellulose is 0.3 times of the weight of quercetin, and the amount of hydroxypropyl methylcellulose is 0.04 times of the weight of quercetin times.

[0041] Preparation:

[0042] Step 1: Take the prescribed amount of quercetin, miltefosine, hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropyl cellulose, and hydroxypropyl methylcellulose and pass through an 80-mesh sieve for later use, and take hydroxypropyl cellulose Base methyl cellulose is added water to make the aqueous solution that mass percent concentration is 2% for subsequent use;

[0043] Step 2: Take the prescribed amount of hydroxypr...

Embodiment 3

[0045] Example 3 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0046]

[0047] Excipients: hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropylcellulose, hydroxypropylmethylcellulose and water. The amount of hydroxypropyl-β-cyclodextrin is 1.2 times of the weight of quercetin, the amount of low-substituted hydroxypropyl cellulose is 0.3 times of the weight of quercetin, and the amount of hydroxypropyl methylcellulose is 0.04 times of the weight of quercetin times.

[0048] Preparation:

[0049] Step 1: Take the prescribed amount of quercetin, miltefosine, hydroxypropyl-β-cyclodextrin, low-substituted hydroxypropyl cellulose, and hydroxypropyl methylcellulose and pass through an 80-mesh sieve for later use, and take hydroxypropyl cellulose Base methyl cellulose is added water to make the aqueous solution that mass percent concentration is 2% for subsequent use;

[0050] Step 2: Take the prescribed amount of hydroxypr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs the field of pharmacy, and particularly relates to a pharmaceutical composition for treating post-myocardial-infarction ventricular remodeling. The pharmaceutical composition fortreating the post-myocardial-infarction ventricular remodeling is prepared from pharmaceutically acceptable pharmaceutic adjuvants, quercetin and miltefosine, wherein 209-435 parts by weight of quercetin and 20-28 parts by weight of miltefosine are used. The dosage form of the pharmaceutical composition for treating the post-myocardial-infarction ventricular remodeling is an oral solid preparation and is preferably an oral granule preparation. When quercetin and miltefosine are combined for drug administration, miltefosine has an unexpected synergistic effect on the post-myocardial-infarctionventricular remodeling resistance effect of quercetin.

Description

technical field [0001] The invention belongs to the field of medicine, in particular to a pharmaceutical composition for treating ventricular remodeling after myocardial infarction. Background technique [0002] Myocardial infarction is a kind of cardiovascular disease clinically based on myocardial ischemic injury. The disease is based on coronary artery disease, which is caused by partial or complete occlusion of coronary arteries, reduced or interrupted blood flow, resulting in local necrosis of the myocardium due to ischemia. Patients often present with severe retrosternal pain, fever, leukocytosis, accelerated erythrocyte sedimentation rate, and progressive electrocardiographic changes. In severe cases, arrhythmia or heart failure may occur. [0003] Over the past 30 years, due to the effective use of drugs such as aspirin, β-blockers, thrombolytic therapy, statins, angiotensin-converting enzyme inhibitors, and clopidogrel, as well as the promotion of interventional th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/661A61K9/16A61K47/69A61P9/10A61P9/00
CPCA61K9/1652A61K31/352A61K31/661A61K2300/00
Inventor 岳红王全政
Owner 岳红
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com